November 9, 2018

Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018

Allison Gatlin
Investor's Business News

October 3, 2017

Balancing the up and downstream: Repligen CEO talks R&D and M&A

by Dan Stanton
Biopharma Reporter

June 23, 2017

Repligen agrees to buy Spectrum for $359 million

by Robert Weisman
Boston Globe

December 20, 2016

Repligen adds single-use filtration technology through TangenX acquisition

by Dan Stanton
BioPharma Reporter

December 15, 2016

Repligen pays $40 million to buy TangenX Technology

by Robert Weisman
The Boston Globe

Sondra Newman
Senior Director, Investor Relations

Phone: 781.250.0111
Toll-free: 800.622.2259
Fax: 781.250.0115

Scroll To Top